🔗 Share this article

This year's Nobel Prize in medical science was granted for revolutionary discoveries that clarify how the immune system targets dangerous infections while sparing the body's own cells.

Three renowned researchers—Japan's Prof. Sakaguchi and American experts Dr. Brunkow and Dr. Ramsdell—received this accolade.

Their research uncovered unique "sentinels" within the defense system that eliminate rogue defense cells that could harming the body.

These discoveries are now enabling new treatments for autoimmune diseases and cancer.

These laureates will share a prize fund worth 11m SEK.

Decisive Findings

"Their work has been essential for comprehending how the body's defenses operates and why we don't all suffer from serious self-attack conditions," stated the chair of the award panel.

The trio's research explain a fundamental mystery: In what way does the immune system defend us from numerous infections while leaving our healthy cells unharmed?

The immune system employs white blood cells that search for indicators of disease, even pathogens and bacteria it has never encountered.

These defenders utilize detectors—known as receptors—that are produced by chance in a vast number of combinations.

This provides the defense network the ability to combat a wide array of threats, but the randomness of the mechanism inevitably produces white blood cells that may target the body.

Protectors of the Immune System

Scientists previously understood that a portion of these problematic white blood cells were destroyed in the immune organ—the site where immune cells mature.

This year's Nobel Prize recognizes the discovery of T-reg cells—described as the body's "security guards"—which patrol the body to disarm any immune cells that assault the healthy cells.

It is known that this process fails in self-attack conditions such as juvenile diabetes, MS, and rheumatoid arthritis.

A Nobel panel stated, "The discoveries have established a new field of research and spurred the development of innovative treatments, for instance for tumors and immune disorders."

Regarding cancer, regulatory T-cells block the system from attacking the tumor, so studies are focused on lowering their numbers.

For self-attack disorders, trials are testing boosting T-reg cells so the organism is no longer under attack. A similar approach could also be useful in reducing the risks of organ transplant rejection.

Pioneering Studies

Professor Sakaguchi, of a Japanese institution, performed tests on mice that had their thymus removed, leading to self-attack conditions.

The researcher demonstrated that introducing immune cells from healthy animals could stop the disease—implying there was a mechanism for blocking immune cells from attacking the body.

Dr. Brunkow, from the Institute for Systems Biology in Seattle, and Fred Ramsdell, now at a biotech firm in a California city, were studying an genetic immune disorder in mice and people that led to the identification of a genetic factor critical for how regulatory T-cells function.

"The groundbreaking research has revealed how the immune system is kept in check by regulatory T cells, preventing it from accidentally attacking the healthy cells," said a leading physiology specialist.

"The work is a remarkable example of how fundamental physiological study can have far-reaching consequences for human health."